argenx SE (NASDAQ:ARGX) Stock Position Raised by SG Americas Securities LLC

SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX) by 6.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 358 shares of the company’s stock after purchasing an additional 21 shares during the period. SG Americas Securities LLC’s holdings in argenx were worth $220,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cromwell Holdings LLC boosted its holdings in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares during the period. GAMMA Investing LLC lifted its position in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares in the last quarter. Fulton Bank N.A. acquired a new stake in shares of argenx during the 4th quarter valued at $226,000. Blue Trust Inc. grew its holdings in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after acquiring an additional 298 shares in the last quarter. Finally, Keudell Morrison Wealth Management acquired a new position in shares of argenx in the third quarter worth $207,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ARGX has been the subject of a number of research reports. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $515.00 to $650.00 in a research report on Friday, November 1st. Wedbush reiterated an “outperform” rating and set a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Guggenheim lifted their target price on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Piper Sandler increased their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $658.39.

argenx Trading Down 1.7 %

ARGX opened at $646.64 on Friday. The stock has a market capitalization of $39.29 billion, a price-to-earnings ratio of -734.82 and a beta of 0.58. The business has a 50 day moving average of $636.51 and a 200-day moving average of $574.93. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.